127 related articles for article (PubMed ID: 24375034)
1. Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption.
Lin ZZ; Chou CH; Cheng AL; Liu WL; Chia-Hsien Cheng J
Int J Cancer; 2014 Jul; 135(2):492-501. PubMed ID: 24375034
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma.
Lu YS; Chou CH; Tzen KY; Gao M; Cheng AL; Kulp SK; Cheng JC
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e181-9. PubMed ID: 22381897
[TBL] [Abstract][Full Text] [Related]
3. The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma.
Lin ZZ; Hsu HC; Hsu CH; Yeh PY; Huang CY; Huang YF; Chen TJ; Kuo SH; Hsu C; Hu FC; Jeng YM; Chung Y; Cheng AL
J Hepatol; 2009 Mar; 50(3):518-27. PubMed ID: 19155085
[TBL] [Abstract][Full Text] [Related]
4. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
6. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma.
Nakao K; Tanaka S; Miura T; Sato K; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Tanabe M
Cancer Sci; 2015 Aug; 106(8):1016-22. PubMed ID: 26011703
[TBL] [Abstract][Full Text] [Related]
7. Sonic Hedgehog inhibition as a strategy to augment radiosensitivity of hepatocellular carcinoma.
Tsai CL; Hsu FM; Tzen KY; Liu WL; Cheng AL; Cheng JC
J Gastroenterol Hepatol; 2015 Aug; 30(8):1317-24. PubMed ID: 25682950
[TBL] [Abstract][Full Text] [Related]
8. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
9. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma.
Liu WL; Gao M; Tzen KY; Tsai CL; Hsu FM; Cheng AL; Cheng JC
Oncotarget; 2014 Jun; 5(11):3662-72. PubMed ID: 25004403
[TBL] [Abstract][Full Text] [Related]
10. Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy.
Talarico C; D'Antona L; Scumaci D; Barone A; Gigliotti F; Fiumara CV; Dattilo V; Gallo E; Visca P; Ortuso F; Abbruzzese C; Botta L; Schenone S; Cuda G; Alcaro S; Bianco C; Lavia P; Paggi MG; Perrotti N; Amato R
Oncotarget; 2015 Nov; 6(35):37511-25. PubMed ID: 26462020
[TBL] [Abstract][Full Text] [Related]
11. Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia-mutated kinase-mediated DNA damage response.
Huang CY; Hsieh FS; Wang CY; Chen LJ; Chang SS; Tsai MH; Hung MH; Kuo CW; Shih CT; Chao TI; Chen KF
Eur J Cancer; 2018 Oct; 102():10-22. PubMed ID: 30103095
[TBL] [Abstract][Full Text] [Related]
12. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
13. Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity.
Zhou Y; Li M; Yu X; Liu T; Li T; Zhou L; Liu W; Li W; Gao F
Int J Biol Sci; 2018; 14(11):1521-1534. PubMed ID: 30263005
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic combination sequentially targeting aurora B and Bcl-xL in hepatocellular carcinoma.
Matsunaga H; Tanaka S; Aihara A; Ogawa K; Matsumura S; Ban D; Ochiai T; Irie T; Kudo A; Nakamura N; Arii S; Tanabe M
Ann Surg Oncol; 2015 Sep; 22(9):3079-86. PubMed ID: 25524010
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
16. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice.
Tsai CL; Liu WL; Hsu FM; Yang PS; Yen RF; Tzen KY; Cheng AL; Chen PJ; Cheng JC
Hepatology; 2018 Feb; 67(2):586-599. PubMed ID: 28646552
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
Chung EJ; Brown AP; Asano H; Mandler M; Burgan WE; Carter D; Camphausen K; Citrin D
Clin Cancer Res; 2009 May; 15(9):3050-7. PubMed ID: 19366835
[TBL] [Abstract][Full Text] [Related]
19. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway.
Shen ZT; Chen Y; Huang GC; Zhu XX; Wang R; Chen LB
BMC Cancer; 2019 Nov; 19(1):1075. PubMed ID: 31703572
[TBL] [Abstract][Full Text] [Related]
20. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
